Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) As Distinct Subsets

Overview

Journal Cancer Med

Specialty Oncology

Date 2025 Feb 14

PMID 39950716

Authors

Zhaohui Liao Arter

Alexandria T M Lee

Misako Nagasaka

Sai-Hong Ignatius Ou

Affiliations

Soon will be listed here.

Abstract

Background: Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor-agnostic manner. However, the objective response rate was the lowest among entrectinib-treated NTRK+ colorectal cancer (CRC) (20%) and selpercatinib-treated RET+ CRC (20%) among all NTRK+, and RET+ solid tumors, respectively.

Methods: We compared tumor mutation burden (TMB) in NTRK+/RET+ CRC with all other NTRK+ and RET+ solid tumors using the American Association for Cancer Research (AACR) GENIE database (Version 13.0).

Results: We identified 14,812 unique CRC patients. Considering only samples with identified fusion partners, the mean TMB was 66.6 ± 15.8 (mt/MB) for NTRK+ CRC (N = 9) and 35 ± 11.5 for RET+ CRC (N = 4), which were significantly higher when compared to the mean number of 6.2 ± 5.4 of TMB for all other RTK+ CRC (N = 30, p < 0.05). Furthermore, NTRK+ CRC harbored significantly higher TMB than RET+ CRC (p = 0.003). In comparison, the mean TMB was 4.0 ± 1.9 for RET+ NSCLC (N = 65) and 2.6 ± 1.6 for RET+ Thyroid cancer (N = 52). Mean TMB for all other NTRK+ solid tumors was < 11 and significantly lower than the mean TMB of NTRK+ CRC. 1482 (10.0%) CRC patients had their MSI status reported. Three out of three NTRK+ CRC patients with known MSI status were all dMMR (100%). 0 out of 12 non-NTRK/non-RET RTK+ CRC patients were dMMR (0%).

Conclusions: NRTK+ and RET+ CRC possess significantly higher TMB than other RTK+ CRC or NTRK+/RET+ non-CRC solid tumors. TMB testing should be routinely done in MSI-H CRC, and TMB ≥ 35 mut/MB samples should be screened for NTRK and RET fusions as an enrichment strategy to provide additional treatment for NTRK+ and RET+ CRC patients.

References

Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak M, Kim C . Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Transl Oncol. 2023; 36:101744. PMC: 10410168. DOI: 10.1016/j.tranon.2023.101744. View

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

Gouda M, Nelson B, Buschhorn L, Wahida A, Subbiah V . Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023; 29(15):2753-2760. PMC: 10390861. DOI: 10.1158/1078-0432.CCR-23-0090. View

Parikh A, He Y, Hong T, Corcoran R, Clark J, Ryan D . Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist. 2019; 24(10):1340-1347. PMC: 6795150. DOI: 10.1634/theoncologist.2019-0034. View

Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T . SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR V600E-mutant mCRC. Future Oncol. 2023; 20(11):653-663. DOI: 10.2217/fon-2022-1249. View

Shaw A, Hsu P, Awad M, Engelman J . Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013; 13(11):772-87. PMC: 3902129. DOI: 10.1038/nrc3612. View

Rousseau B, Foote M, Maron S, Diplas B, Lu S, Argiles G . The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. N Engl J Med. 2021; 384(12):1168-1170. PMC: 8403269. DOI: 10.1056/NEJMc2031965. View

Schrock A, Devoe C, McWilliams R, Sun J, Aparicio T, Stephens P . Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017; 3(11):1546-1553. PMC: 5710195. DOI: 10.1001/jamaoncol.2017.1051. View

Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J . Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022; 23(10):1261-1273. PMC: 11702314. DOI: 10.1016/S1470-2045(22)00541-1. View

10.

Hong D, Dubois S, Kummar S, Farago A, Albert C, Rohrberg K . Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020; 21(4):531-540. PMC: 7497841. DOI: 10.1016/S1470-2045(19)30856-3. View

11.

Schram A, Chang M, Jonsson P, Drilon A . Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017; 14(12):735-748. PMC: 10452928. DOI: 10.1038/nrclinonc.2017.127. View

12.

Andre T, Lonardi S, Wong K, Lenz H, Gelsomino F, Aglietta M . Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022; 33(10):1052-1060. DOI: 10.1016/j.annonc.2022.06.008. View

13.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

14.

Anaya J, Sidhom J, Cummings C, Baras A . Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing. Cancer Res Commun. 2023; 3(3):501-509. PMC: 10044680. DOI: 10.1158/2767-9764.CRC-22-0339. View

15.

Fakih M, Salvatore L, Esaki T, Modest D, Lopez-Bravo D, Taieb J . Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C. N Engl J Med. 2023; 389(23):2125-2139. DOI: 10.1056/NEJMoa2308795. View

16.

Marcus L, Donoghue M, Aungst S, Myers C, Helms W, Shen G . FDA Approval Summary: Entrectinib for the Treatment of gene Fusion Solid Tumors. Clin Cancer Res. 2020; 27(4):928-932. DOI: 10.1158/1078-0432.CCR-20-2771. View

17.

Yang S, Aypar U, Rosen E, Mata D, Benayed R, Mullaney K . A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clin Cancer Res. 2020; 27(5):1316-1328. PMC: 8285056. DOI: 10.1158/1078-0432.CCR-20-3208. View

18.

Subbiah V, Cassier P, Siena S, Garralda E, Paz-Ares L, Garrido P . Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat Med. 2022; 28(8):1640-1645. PMC: 9388374. DOI: 10.1038/s41591-022-01931-y. View

19.

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

20.

Wang H, Li Z, Ou Q, Wu X, Nagasaka M, Shao Y . NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 2022; 11(13):2541-2549. PMC: 9249987. DOI: 10.1002/cam4.4561. View